Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes.
Facteurs de risqueMaladies auto-immunesLupus érythémateux
#2
L'âge influence-t-il le risque ?
Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans.
ÂgeRisqueLupus érythémateux
#3
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique.
Antécédents médicauxMaladies auto-immunesRisque
#4
Le stress peut-il être un facteur de risque ?
Oui, le stress peut exacerber les symptômes et augmenter le risque de complications.
StressRisqueComplications
#5
Y a-t-il des facteurs environnementaux ?
Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur.
EnvironnementMédicamentsFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteur lupique de la coagulation : Questions médicales les plus fréquentes",
"headline": "Inhibiteur lupique de la coagulation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteur lupique de la coagulation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-16",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"url": "https://questionsmedicales.fr/mesh/D019774",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"code": {
"@type": "MedicalCode",
"code": "D019774",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.113"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation",
"alternateName": "Lupus Coagulation Inhibitor",
"code": {
"@type": "MedicalCode",
"code": "D016682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Schmitz",
"url": "https://questionsmedicales.fr/author/Thomas%20Schmitz",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Charlotte A Bäuml",
"url": "https://questionsmedicales.fr/author/Charlotte%20A%20B%C3%A4uml",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Diana Imhof",
"url": "https://questionsmedicales.fr/author/Diana%20Imhof",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de."
}
},
{
"@type": "Person",
"name": "Jeremy W Jacobs",
"url": "https://questionsmedicales.fr/author/Jeremy%20W%20Jacobs",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06520, USA. Jeremy.jacobs@yale.edu."
}
},
{
"@type": "Person",
"name": "Jiraphorn Issara-Amphorn",
"url": "https://questionsmedicales.fr/author/Jiraphorn%20Issara-Amphorn",
"affiliation": {
"@type": "Organization",
"name": "Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Monocyte subsets and monocyte-related chemokines in Takayasu arteritis.",
"datePublished": "2023-02-06",
"url": "https://questionsmedicales.fr/article/36746990",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-29369-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37077911",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1151780"
}
},
{
"@type": "ScholarlyArticle",
"name": "The monocyte monolayer assay, an",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37405851",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21307/immunohematology-2023-010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia.",
"datePublished": "2022-11-30",
"url": "https://questionsmedicales.fr/article/36448679",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cyto.b.22106"
}
},
{
"@type": "ScholarlyArticle",
"name": "Periostin-An inducer of pro-fibrotic phenotype in monocytes and monocyte-derived macrophages in systemic sclerosis.",
"datePublished": "2023-08-02",
"url": "https://questionsmedicales.fr/article/37531393",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0281881"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"item": "https://questionsmedicales.fr/mesh/D019774"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inhibiteur lupique de la coagulation",
"item": "https://questionsmedicales.fr/mesh/D016682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteur lupique de la coagulation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteur lupique de la coagulation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteur lupique de la coagulation",
"description": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les signes cliniques associés ?\nLe diagnostic nécessite-t-il des antécédents médicaux ?\nPeut-on avoir un inhibiteur sans lupus ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Monocytes#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nPeut-on avoir des symptômes sans saignement ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Monocytes#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteur lupique de la coagulation",
"description": "Peut-on prévenir l'inhibiteur lupique ?\nQuels conseils de mode de vie peuvent aider ?\nLes femmes enceintes doivent-elles être surveillées ?\nY a-t-il des vaccinations recommandées ?\nComment gérer le stress pour prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Monocytes#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteur lupique de la coagulation",
"description": "Quels traitements sont disponibles ?\nLes anticoagulants sont-ils toujours nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nLes traitements sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Monocytes#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteur lupique de la coagulation",
"description": "Quelles sont les complications possibles ?\nLes complications sont-elles fréquentes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être graves ?\nY a-t-il des signes d'alerte pour les complications ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Monocytes#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nY a-t-il des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Monocytes#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de coagulation et la détection d'anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de temps de céphaline activée (TCA) et les tests d'anticorps anti-cardiolipine sont courants."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques associés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des saignements anormaux et des thromboses, souvent sans cause apparente."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il des antécédents médicaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de lupus ou d'autres maladies auto-immunes sont importants."
}
},
{
"@type": "Question",
"name": "Peut-on avoir un inhibiteur sans lupus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est possible d'avoir un inhibiteur lupique sans diagnostic de lupus, bien que rare."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements, des ecchymoses, et des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à la grossesse, comme des complications thromboemboliques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans saignement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes thromboemboliques sans saignement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibiteur lupique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels conseils de mode de vie peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance étroite est nécessaire pour prévenir les complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations doivent être discutées avec un médecin, surtout pour les immunodéprimés."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress, comme la méditation, peuvent aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants et des immunosuppresseurs pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les anticoagulants sont-ils toujours nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, leur nécessité dépend de la gravité des symptômes et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent avoir des effets secondaires, comme des saignements ou des infections."
}
},
{
"@type": "Question",
"name": "Le traitement est-il à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la réponse au traitement et de l'évolution de la maladie, souvent à long terme."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des traitements sont efficaces pour contrôler les symptômes et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des thromboses, des AVC et des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent survenir, mais leur fréquence dépend de la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et nécessiter une intervention médicale urgente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte pour les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques ou des troubles neurologiques doivent alerter immédiatement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur."
}
}
]
}
]
}
Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de.
Publications dans "Inhibiteur lupique de la coagulation" :
Translational Research in Inflammation and Immunology Research Unit (TRIRU), Department of Microbiology, Chulalongkorn University, Bangkok, Thailand, aleelahavanit@gmail.com.
Publications dans "Inhibiteur lupique de la coagulation" :
Department of Pathology and Laboratory Medicine , University of North Carolina at Chapel Hill , 819 Brinkhous-Bullitt Building , Chapel Hill , North Carolina 27599 , United States.
Publications dans "Inhibiteur lupique de la coagulation" :
The pathogenesis of Takayasu arteritis (TAK) is poorly understood and no previous studies have analyzed monocytes in TAK. This study evaluated monocyte subsets and monocyte-related chemokines in the p...
Monocytes and macrophages play a pivotal role in inflammation during acute SARS-CoV-2 infection. However, their contribution to the development of post-acute sequelae of SARS-CoV-2 infection (PASC) ar...
A cross-sectional study was conducted comparing plasma cytokine and monocyte levels among three groups: participants with pulmonary PASC (PPASC) with a reduced predicted diffusing capacity for carbon ...
Plasma IL-1Ra levels were elevated but FGF levels were reduced in PG compared to NG. Circulating monocytes and three subsets were significantly higher in PG and RG compared to NG. PG and RG exhibited...
This study present evidence that COVID convalescents exhibit monocyte alteration beyond the acute COVID-19 infection period even in convalescents with no residual symptoms. Further, the results sugges...
It has long been a goal of transfusion medicine scientists to predict which patients will make clinically significant antibodies when transfused with donor red blood cells (RBCs). But this goal has ye...
The presence of >94% classical monocytes (MO1, CD14++/CD16-) in peripheral blood (PB) has an excellent performance for the diagnosis of chronic myelomonocytic leukemia (CMML). However, the monocyte ga...
This is a prospective, single center study assessing monocyte subsets in PB. First, we compared monocyte subsets using 13 monocyte gating strategies in 10 samples. Then we developed our own 10 color t...
Comparing different monocyte gating strategies, small but significant differences in %MO1 and percentually large differences in %MO3 (nonclassical monocytes) were found, suggesting that the monocyte g...
The choice of monocyte gating strategy appears relevant for the monocyte subset distribution test. Our 10-color proposal allowed satisfactory monocyte gating even in highly abnormal PB. Computational ...
Enhanced circulating blood periostin levels positively correlate with disease severity in patients with systemic sclerosis (SSc). Monocytes/macrophages are predominantly associated with the pathogenes...
Head and neck squamous cell carcinomas (HNSCCs) are characterized by an abundance of monocytes and macrophages recruited from the peripheral blood. However, it has not been determined whether these in...
Monocytes play an important role in inflammation, and monocytosis and monocyte activation are features of chronic inflammation. We aimed to investigate if HIV status was associated with monocyte count...
Persons living with HIV (PLWH) with measured monocyte count and sCD14 and sCD163 were included from the Copenhagen Comorbidity in HIV infection (COCOMO) study and matched 1:5 on sex and age with uninf...
We included 871 PLWH and 4355 uninfected controls. PLWH had - 0.021 [- 0.031 - 0.011] × 10...
PLWH had lower monocyte counts than controls, but the absolute difference was small, and any clinical impact is likely limited. In contrast, concentrations of monocyte activation markers, previously i...
Some reports suggest that high absolute monocyte count (AMC) at diagnosis is an independent predictor of poor prognosis in acute myeloid leukemia (AML), but others disagree. Monocytic myeloid-derived ...
Peripheral blood samples from 107 newly diagnosed patients with AML and 47 healthy controls (HCs) were collected. We validated the clinical significance of AMC, monocyte count (CD14...
Compared with HCs, the levels of AMC, monocyte count, and Mo-MDSC count were all significantly higher among patients with AML. However, only elevated Mo-MDSC count was significantly associated with lo...
Mo-MDSCs but not monocytes predict the poor prognosis of AML....
Glioblastoma (GBM) is the most belligerent and frequent brain tumor in adults. Research over the past two decades has provided increased knowledge of the genomic and molecular landscape of GBM and hig...
Monocytes in peripheral blood circulation are the precursor of essential cells that control tumor progression, that include tumor-associated macrophages (TAMs), dendritic cells (DCs) and myeloid-deriv...